Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:LMNX's Cash to Debt is ranked higher than
99% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NAS:LMNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:LMNX' s Cash to Debt Range Over the Past 10 Years
Min: 3.96  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.91
NAS:LMNX's Equity to Asset is ranked higher than
96% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NAS:LMNX: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
NAS:LMNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.89 Max: 0.97
Current: 0.91
0.77
0.97
Interest Coverage No Debt
NAS:LMNX's Interest Coverage is ranked higher than
99% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NAS:LMNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:LMNX' s Interest Coverage Range Over the Past 10 Years
Min: 5.66  Med: 77.41 Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 16.30
M-Score: -2.23
WACC vs ROIC
3.28%
16.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.91
NAS:LMNX's Operating margin (%) is ranked higher than
78% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NAS:LMNX: 14.91 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:LMNX' s Operating margin (%) Range Over the Past 10 Years
Min: -23.22  Med: 7.04 Max: 15.72
Current: 14.91
-23.22
15.72
Net-margin (%) 16.60
NAS:LMNX's Net-margin (%) is ranked higher than
89% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NAS:LMNX: 16.60 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:LMNX' s Net-margin (%) Range Over the Past 10 Years
Min: -3.61  Med: 4.91 Max: 17.2
Current: 16.6
-3.61
17.2
ROE (%) 11.35
NAS:LMNX's ROE (%) is ranked higher than
71% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NAS:LMNX: 11.35 )
Ranked among companies with meaningful ROE (%) only.
NAS:LMNX' s ROE (%) Range Over the Past 10 Years
Min: -3.44  Med: 3.96 Max: 13.24
Current: 11.35
-3.44
13.24
ROA (%) 10.37
NAS:LMNX's ROA (%) is ranked higher than
82% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NAS:LMNX: 10.37 )
Ranked among companies with meaningful ROA (%) only.
NAS:LMNX' s ROA (%) Range Over the Past 10 Years
Min: -2.85  Med: 3.35 Max: 11.77
Current: 10.37
-2.85
11.77
ROC (Joel Greenblatt) (%) 46.11
NAS:LMNX's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NAS:LMNX: 46.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:LMNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12.68  Med: 22.71 Max: 46.11
Current: 46.11
-12.68
46.11
Revenue Growth (3Y)(%) 4.80
NAS:LMNX's Revenue Growth (3Y)(%) is ranked higher than
52% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NAS:LMNX: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:LMNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 21.7 Max: 194.3
Current: 4.8
4.8
194.3
EBITDA Growth (3Y)(%) 10.40
NAS:LMNX's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NAS:LMNX: 10.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:LMNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.9  Med: 9.2 Max: 45.3
Current: 10.4
-66.9
45.3
EPS Growth (3Y)(%) 42.10
NAS:LMNX's EPS Growth (3Y)(%) is ranked higher than
87% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NAS:LMNX: 42.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:LMNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.7  Med: 7.9 Max: 104.9
Current: 42.1
-52.7
104.9
» NAS:LMNX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

LMNX Guru Trades in Q3 2015

Joel Greenblatt 171,460 sh (New)
Chuck Royce 5,900 sh (+84.38%)
Jim Simons 751,203 sh (+39.70%)
Paul Tudor Jones 37,097 sh (-28.92%)
» More
Q4 2015

LMNX Guru Trades in Q4 2015

Joel Greenblatt 209,221 sh (+22.02%)
Paul Tudor Jones 43,487 sh (+17.23%)
Jim Simons 846,040 sh (+12.62%)
Chuck Royce Sold Out
» More
Q1 2016

LMNX Guru Trades in Q1 2016

Jim Simons 1,007,840 sh (+19.12%)
Paul Tudor Jones 36,086 sh (-17.02%)
Joel Greenblatt 62,983 sh (-69.90%)
» More
Q2 2016

LMNX Guru Trades in Q2 2016

Paul Tudor Jones 46,409 sh (+28.61%)
Jim Simons 1,002,900 sh (-0.49%)
Joel Greenblatt 11,923 sh (-81.07%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:ELGX, NAS:MMSI, OTCPK:NNCSF, NAS:NVCR, NAS:ATRI, NYSE:GKOS, NAS:ANGO, NAS:ATRC, OTCPK:TOPCF, NAS:OSUR, NAS:UNIS, NAS:MLAB, NAS:CFMS, NYSE:HYH, NAS:NXTM, NAS:ENTL, NAS:STAA, NAS:LMAT, AMEX:CRHM, NAS:ATRS » details
Traded in other countries:LMX.Germany,
Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, & FLEXMAP 3D.

Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the Company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The Company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.

Ratios

vs
industry
vs
history
P/E(ttm) 23.51
LMNX's P/E(ttm) is ranked higher than
64% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.50 vs. LMNX: 23.51 )
Ranked among companies with meaningful P/E(ttm) only.
LMNX' s P/E(ttm) Range Over the Past 10 Years
Min: 16.42  Med: 62.89 Max: 603.33
Current: 23.51
16.42
603.33
PE(NRI) 23.51
LMNX's PE(NRI) is ranked higher than
63% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.80 vs. LMNX: 23.51 )
Ranked among companies with meaningful PE(NRI) only.
LMNX' s PE(NRI) Range Over the Past 10 Years
Min: 16.42  Med: 62.89 Max: 603.33
Current: 23.51
16.42
603.33
Price/Owner Earnings (ttm) 34.56
LMNX's Price/Owner Earnings (ttm) is ranked lower than
65% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.25 vs. LMNX: 34.56 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LMNX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.73  Med: 59.47 Max: 903.5
Current: 34.56
21.73
903.5
P/B 2.43
LMNX's P/B is ranked higher than
60% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. LMNX: 2.43 )
Ranked among companies with meaningful P/B only.
LMNX' s P/B Range Over the Past 10 Years
Min: 2.02  Med: 3.29 Max: 12.31
Current: 2.43
2.02
12.31
P/S 3.87
LMNX's P/S is ranked lower than
58% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. LMNX: 3.87 )
Ranked among companies with meaningful P/S only.
LMNX' s P/S Range Over the Past 10 Years
Min: 2.87  Med: 5.12 Max: 12.94
Current: 3.87
2.87
12.94
PFCF 23.40
LMNX's PFCF is ranked higher than
66% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. LMNX: 23.40 )
Ranked among companies with meaningful PFCF only.
LMNX' s PFCF Range Over the Past 10 Years
Min: 19.41  Med: 60.14 Max: 440.73
Current: 23.4
19.41
440.73
POCF 17.87
LMNX's POCF is ranked lower than
51% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. LMNX: 17.87 )
Ranked among companies with meaningful POCF only.
LMNX' s POCF Range Over the Past 10 Years
Min: 12.21  Med: 30.95 Max: 270
Current: 17.87
12.21
270
EV-to-EBIT 20.79
LMNX's EV-to-EBIT is ranked higher than
51% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. LMNX: 20.79 )
Ranked among companies with meaningful EV-to-EBIT only.
LMNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -999.3  Med: 31.85 Max: 632.6
Current: 20.79
-999.3
632.6
EV-to-EBITDA 15.19
LMNX's EV-to-EBITDA is ranked higher than
60% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. LMNX: 15.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
LMNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105217.5  Med: 24.95 Max: 4060.3
Current: 15.19
-105217.5
4060.3
PEG 1.65
LMNX's PEG is ranked higher than
76% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. LMNX: 1.65 )
Ranked among companies with meaningful PEG only.
LMNX' s PEG Range Over the Past 10 Years
Min: 1.02  Med: 1.87 Max: 6.34
Current: 1.65
1.02
6.34
Shiller P/E 58.84
LMNX's Shiller P/E is ranked lower than
76% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. LMNX: 58.84 )
Ranked among companies with meaningful Shiller P/E only.
LMNX' s Shiller P/E Range Over the Past 10 Years
Min: 50.76  Med: 110.63 Max: 1224.5
Current: 58.84
50.76
1224.5
Current Ratio 4.79
LMNX's Current Ratio is ranked higher than
83% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. LMNX: 4.79 )
Ranked among companies with meaningful Current Ratio only.
LMNX' s Current Ratio Range Over the Past 10 Years
Min: 2.39  Med: 8.2 Max: 59.71
Current: 4.79
2.39
59.71
Quick Ratio 3.54
LMNX's Quick Ratio is ranked higher than
79% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. LMNX: 3.54 )
Ranked among companies with meaningful Quick Ratio only.
LMNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.86  Med: 7.14 Max: 58.8
Current: 3.54
1.86
58.8
Days Inventory 165.30
LMNX's Days Inventory is ranked lower than
70% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. LMNX: 165.30 )
Ranked among companies with meaningful Days Inventory only.
LMNX' s Days Inventory Range Over the Past 10 Years
Min: 69.92  Med: 155.77 Max: 182.42
Current: 165.3
69.92
182.42
Days Sales Outstanding 39.66
LMNX's Days Sales Outstanding is ranked higher than
83% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. LMNX: 39.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.52  Med: 53.46 Max: 66.89
Current: 39.66
38.52
66.89
Days Payable 56.19
LMNX's Days Payable is ranked higher than
57% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. LMNX: 56.19 )
Ranked among companies with meaningful Days Payable only.
LMNX' s Days Payable Range Over the Past 10 Years
Min: 36.85  Med: 56.62 Max: 78.2
Current: 56.19
36.85
78.2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.20
LMNX's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. LMNX: -1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LMNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.8  Med: -2.7 Max: 0.4
Current: -1.2
-30.8
0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 23.03
LMNX's Price/Net Cash is ranked lower than
62% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.23 vs. LMNX: 23.03 )
Ranked among companies with meaningful Price/Net Cash only.
LMNX' s Price/Net Cash Range Over the Past 10 Years
Min: 3.74  Med: 10.53 Max: 135.19
Current: 23.03
3.74
135.19
Price/Net Current Asset Value 8.09
LMNX's Price/Net Current Asset Value is ranked higher than
51% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. LMNX: 8.09 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LMNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.85  Med: 7.1 Max: 40.76
Current: 8.09
2.85
40.76
Price/Tangible Book 4.20
LMNX's Price/Tangible Book is ranked higher than
54% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. LMNX: 4.20 )
Ranked among companies with meaningful Price/Tangible Book only.
LMNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.66  Med: 5.44 Max: 16.96
Current: 4.2
2.66
16.96
Price/Projected FCF 1.46
LMNX's Price/Projected FCF is ranked higher than
64% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. LMNX: 1.46 )
Ranked among companies with meaningful Price/Projected FCF only.
LMNX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.28  Med: 2.96 Max: 11.2
Current: 1.46
1.28
11.2
Price/Median PS Value 0.76
LMNX's Price/Median PS Value is ranked higher than
81% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. LMNX: 0.76 )
Ranked among companies with meaningful Price/Median PS Value only.
LMNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 1.34 Max: 52.04
Current: 0.76
0.58
52.04
Price/Peter Lynch Fair Value 1.88
LMNX's Price/Peter Lynch Fair Value is ranked higher than
59% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.22 vs. LMNX: 1.88 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LMNX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.24  Med: 3.13 Max: 25.89
Current: 1.88
1.24
25.89
Price/Graham Number 2.10
LMNX's Price/Graham Number is ranked higher than
65% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. LMNX: 2.10 )
Ranked among companies with meaningful Price/Graham Number only.
LMNX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.5  Med: 4.03 Max: 16.53
Current: 2.1
1.5
16.53
Earnings Yield (Greenblatt) (%) 4.85
LMNX's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. LMNX: 4.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LMNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.5 Max: 7.2
Current: 4.85
0.2
7.2
Forward Rate of Return (Yacktman) (%) 15.12
LMNX's Forward Rate of Return (Yacktman) (%) is ranked higher than
73% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. LMNX: 15.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LMNX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -53.6  Med: 0.7 Max: 29
Current: 15.12
-53.6
29

More Statistics

Revenue (TTM) (Mil) $248.2
EPS (TTM) $ 0.96
Beta0.22
Short Percentage of Float10.77%
52-Week Range $16.16 - 23.75
Shares Outstanding (Mil)43.55

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 0.61
EPS w/o NRI ($) 0.61
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 

More From Other Websites
Luminex Corp. – Value Analysis (NASDAQ:LMNX) : September 19, 2016 Sep 19 2016
Luminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : September 16, 2016 Sep 16 2016
LUMINEX CORP Files SEC form 8-K, Change in Directors or Principal Officers Sep 09 2016
Luminex Poised on Pipeline Strength, System Sales Upbeat Aug 30 2016
ETF’s with exposure to Luminex Corp. : August 26, 2016 Aug 26 2016
LUMINEX CORP Files SEC form 8-K/A, Financial Statements and Exhibits Aug 25 2016
Luminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : August 25, 2016 Aug 25 2016
Luminex upgraded by JP Morgan Aug 18 2016
ETF’s with exposure to Luminex Corp. : August 15, 2016 Aug 15 2016
Luminex (LMNX) Receives FDA Clearance for xMAP Assay Aug 15 2016
Are You Watching Medpace's IPO? Don't Ignore Its Larger Rival Aug 12 2016
Luminex Corp. :LMNX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Will This Clinical Researcher Become Next Breakout Medical Stock? Aug 11 2016
PRA Health Sciences Vs. Medpace: How 2 Medical IPOs Stack Up Aug 11 2016
Biotech firm joins fight against Zika Aug 10 2016
Luminex Corporation Receives FDA Clearance for New Molecular Test for Identification and... Aug 08 2016
Luminex Corporation Receives FDA Emergency Use Authorization for Zika Virus Molecular Detection... Aug 08 2016
LUMINEX CORP Financials Aug 04 2016
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat Aug 03 2016
Luminex Corporation Reports Second Quarter 2016 Results Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)